Wall Street brokerages expect that Unity Biotechnology Inc (NASDAQ:UBX) will report earnings per share (EPS) of ($0.54) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Unity Biotechnology’s earnings. Unity Biotechnology posted earnings per share of ($0.48) during the same quarter last year, which would indicate a negative year-over-year growth rate of 12.5%. The business is expected to announce its next earnings report on Wednesday, March 4th.
According to Zacks, analysts expect that Unity Biotechnology will report full-year earnings of ($2.00) per share for the current fiscal year, with EPS estimates ranging from ($2.07) to ($1.93). For the next year, analysts forecast that the firm will report earnings of ($2.09) per share, with EPS estimates ranging from ($2.25) to ($1.93). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Unity Biotechnology.
A number of brokerages recently issued reports on UBX. ValuEngine raised Unity Biotechnology from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Unity Biotechnology in a research note on Thursday, October 17th. Mizuho reissued a “buy” rating and set a $33.00 price target on shares of Unity Biotechnology in a research note on Monday. Finally, Zacks Investment Research lowered Unity Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, October 12th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Unity Biotechnology currently has an average rating of “Buy” and an average price target of $19.50.
Shares of UBX stock traded down $0.12 on Monday, reaching $6.81. 20,573 shares of the company’s stock were exchanged, compared to its average volume of 240,684. Unity Biotechnology has a 52 week low of $5.61 and a 52 week high of $17.46. The stock has a market capitalization of $300.46 million, a PE ratio of -2.68 and a beta of -0.16. The company’s fifty day simple moving average is $6.76 and its 200 day simple moving average is $7.47.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of Montreal Can raised its position in Unity Biotechnology by 164,400.0% during the 2nd quarter. Bank of Montreal Can now owns 4,935 shares of the company’s stock valued at $47,000 after purchasing an additional 4,932 shares in the last quarter. Aperio Group LLC bought a new stake in Unity Biotechnology during the 2nd quarter valued at $50,000. Northern Trust Corp raised its position in Unity Biotechnology by 2.4% during the 2nd quarter. Northern Trust Corp now owns 242,690 shares of the company’s stock valued at $2,306,000 after purchasing an additional 5,756 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Unity Biotechnology by 9.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 69,516 shares of the company’s stock worth $660,000 after acquiring an additional 6,112 shares in the last quarter. Finally, Tower Research Capital LLC TRC bought a new position in shares of Unity Biotechnology in the 3rd quarter worth $45,000. 36.77% of the stock is owned by institutional investors and hedge funds.
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.
Featured Article: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.